Moderna, Inc. (NASDAQ:MRNA) Receives $80.53 Average Target Price from Brokerages

Moderna, Inc. (NASDAQ:MRNA) has been assigned a consensus recommendation of “Hold” from the twenty-three analysts that are currently covering the firm, Marketbeat.com reports. Three research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and seven have assigned a buy rating to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $80.5294.

A number of brokerages recently issued reports on MRNA. Loop Capital set a $135.00 price objective on Moderna in a research note on Wednesday, August 19th. UBS Group increased their target price on shares of Moderna from $50.00 to $150.00 and gave the stock a “neutral” rating in a research report on Thursday, August 20th. Piper Sandler reiterated an “overweight” rating on shares of Moderna in a research note on Monday, August 3rd. The Goldman Sachs Group lifted their target price on shares of Moderna from $67.00 to $120.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 19th. Finally, Wolfe Research raised shares of Moderna from an “underperform” rating to a “peer perform” rating in a research report on Tuesday, August 25th.

Insiders Place Their Bets

In related news, President Stephen Hoge sold 53,336 shares of Moderna stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $51.37, for a total value of $2,739,870.32. Following the completion of the transaction, the president directly owned 1,483,848 shares in the company, valued at approximately $76,225,271.76. The trade was a 3.47% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 10.80% of the company’s stock.

Hedge Funds Weigh In On Moderna

Large investors have recently made changes to their positions in the stock. MUFG Securities EMEA plc bought a new stake in shares of Moderna during the 2nd quarter valued at $28,000. Allied Private Wealth LLC bought a new position in Moderna in the 2nd quarter worth about $30,000. Canton Hathaway LLC bought a new position in Moderna in the 1st quarter worth about $31,000. Archer Investment Corp purchased a new position in Moderna during the 2nd quarter valued at about $36,000. Finally, EverSource Wealth Advisors LLC grew its holdings in Moderna by 148.3% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,341 shares of the company’s stock valued at $37,000 after buying an additional 801 shares in the last quarter. 75.33% of the stock is owned by institutional investors.

Moderna Stock Performance

NASDAQ:MRNA opened at $150.81 on Monday. The company has a market capitalization of $60.21 billion, a P/E ratio of -18.87 and a beta of 1.10. The business has a fifty day simple moving average of $82.40 and a two-hundred day simple moving average of $62.12. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.29 and a quick ratio of 2.18. Moderna has a 1 year low of $22.28 and a 1 year high of $176.66.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Friday, July 31st. The company reported ($1.97) EPS for the quarter, beating analysts’ consensus estimates of ($2.03) by $0.06. The firm had revenue of $145.00 million for the quarter, compared to analysts’ expectations of $102.93 million. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%.The business’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($2.13) EPS. On average, analysts expect that Moderna will post -6.09 earnings per share for the current year.

Trending Headlines about Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna’s personalized melanoma vaccine with Merck delivered positive late-stage trial results, reinforcing the potential for a commercially significant oncology business beyond COVID-19 vaccines. The development has been a major driver of the stock’s recent rally. Moderna Stock Climbs Following Melanoma Trial Success and Vaccine Approval
• Positive Sentiment: The FDA approved Moderna’s new mRNA seasonal flu vaccine for adults, expanding the company’s commercial vaccine opportunity and validating its mRNA platform. FDA Approves New mRNA Flu Vaccine for Adults
• Positive Sentiment: Brookline Capital Markets raised its 2026–2028 EPS forecasts and maintained a “Buy” rating, including a projected return to profitability in 2028. The revisions suggest improving expectations for Moderna’s cost structure and pipeline revenue. Brookline Capital Markets Estimates
• Positive Sentiment: Commentator Jim Cramer argued that Moderna’s heavy short interest could fuel additional gains if bearish investors continue covering positions. Elevated call-option activity and short-squeeze screens are adding speculative buying interest. Jim Cramer Discusses Moderna’s Short-Squeeze Potential
• Neutral Sentiment: Moderna will present at healthcare investor conferences in September, creating potential catalysts for updates on its pipeline, commercial plans and financial outlook.
• Negative Sentiment: GSK advanced a competing mRNA flu vaccine into Phase III development. While Moderna currently has a first-mover advantage, the move could increase long-term competition in a market investors are increasingly valuing. GSK Advances Rival mRNA Flu Vaccine
• Negative Sentiment: After more than doubling in August, MRNA may be experiencing profit-taking and heightened volatility. Brookline also modestly reduced its longer-term 2029–2030 EPS estimates, tempering some of the bullish outlook.

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.